MFWM
BMRN icon

Motley Fool Wealth Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Motley Fool Wealth Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$202K Sell
3,533
-244,344
-99% -$13.4M 3.07% 17
2026
Q1 		$14M Sell
247,877
-82,976
-25% -$4.84M 1.58% 20
2025
Q4 		$19.7M Sell
330,853
-85,023
-20% -$4.63M 1.53% 16
2025
Q3 		$22.5M Sell
415,876
-60,073
-13% -$3.44M 1.53% 16
2025
Q2 		$26.2M Buy
475,949
+126,970
+36% +$7.48M 1.58% 14
2025
Q1 		$24.7M Buy
348,979
+1,251
+0.4% +$84.2K 1.46% 18
2024
Q4 		$22.7M Sell
347,728
-76,869
-18% -$5.15M 1.17% 21
2024
Q3 		$29.8M Sell
424,597
-21,106
-5% -$1.76M 1.5% 15
2024
Q2 		$36.7M Sell
445,703
-13,032
-3% -$1.08M 1.87% 13
2024
Q1 		$40.1M Sell
458,735
-11,554
-2% -$1.03M 2.07% 11
2023
Q4 		$45.4M Sell
470,289
-18,667
-4% -$1.65M 2.38% 10
2023
Q3 		$43.3M Buy
488,956
+159,421
+48% +$14.2M 2.5% 9
2023
Q2 		$28.6M Sell
329,535
-7,271
-2% -$684K 1.68% 16
2023
Q1 		$32.8M Sell
336,806
-1,836
-0.5% -$190K 2.05% 14
2022
Q4 		$35M Sell
338,642
-4,247
-1% -$399K 2.43% 8
2022
Q3 		$29.1M Sell
342,889
-6,100
-2% -$543K 1.9% 14
2022
Q2 		$28.9M Sell
348,989
-8,001
-2% -$637K 1.82% 16
2022
Q1 		$27.5M Buy
356,990
+128,822
+56% +$10.8M 1.31% 23
2021
Q4 		$20.2M Sell
228,168
-5,535
-2% -$457K 0.88% 38
2021
Q3 		$18.1M Sell
233,703
-6,807
-3% -$537K 0.79% 43
2021
Q2 		$20.1M Sell
240,510
-3,811
-2% -$302K 0.84% 41
2021
Q1 		$18.4M Sell
244,321
-2,560
-1% -$209K 0.83% 43
2020
Q4 		$21.6M Buy
246,881
+1,792
+0.7% +$142K 0.96% 37
2020
Q3 		$18.6M Buy
245,089
+1,528
+0.6% +$155K 0.97% 32
2020
Q2 		$30M Sell
243,561
-7,188
-3% -$714K 1.71% 12
2020
Q1 		$21.2M Sell
250,749
-12,511
-5% -$1.08M 1.53% 19
2019
Q4 		$22.3M Buy
+263,260
New +$19.9M 1.34% 21

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Motley Fool Wealth Management's BMRN Position: Q2 2026 in Review

Motley Fool Wealth Management reduced its BioMarin Pharmaceuticals (BMRN) stake by 99% in Q2 2026, selling an estimated $13.4M and leaving 3,533 shares worth $202K. The position accounts for 3.07% of the portfolio, ranked #17.

Motley Fool Wealth Management first reported a position in BMRN in Q4 2019 and has held it in 27 quarters since. The position peaked at $45.4M in Q4 2023. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Motley Fool Wealth Management held 3,533 shares of BioMarin Pharmaceuticals worth $202K as of Q2 2026.
  • Motley Fool Wealth Management sold 244,344 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $13.4M.
  • BioMarin Pharmaceuticals made up 3.07% of Motley Fool Wealth Management's portfolio in Q2 2026, its #17 holding.
  • Motley Fool Wealth Management first reported a position in BioMarin Pharmaceuticals in Q4 2019 and has held it in 27 quarters since.
  • Motley Fool Wealth Management's BioMarin Pharmaceuticals position peaked at $45.4M in Q4 2023.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Motley Fool Wealth Management's 13F filing for Q2 2026, filed 6 Aug 2026.